nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—sarcoma	0.478	0.803	CbGbCtD
Orlistat—CYP3A4—Thiotepa—sarcoma	0.0538	0.0904	CbGbCtD
Orlistat—CYP3A4—Mitoxantrone—sarcoma	0.0231	0.0389	CbGbCtD
Orlistat—CYP3A4—Vincristine—sarcoma	0.0159	0.0268	CbGbCtD
Orlistat—CYP3A4—Etoposide—sarcoma	0.0146	0.0245	CbGbCtD
Orlistat—CYP3A4—Doxorubicin—sarcoma	0.00996	0.0167	CbGbCtD
Orlistat—DAGLB—mammary gland—sarcoma	0.00936	0.0587	CbGeAlD
Orlistat—ABHD12—mammary gland—sarcoma	0.00665	0.0417	CbGeAlD
Orlistat—LIPF—testis—sarcoma	0.00625	0.0392	CbGeAlD
Orlistat—FASN—mammary gland—sarcoma	0.00558	0.035	CbGeAlD
Orlistat—PLA2G7—myometrium—sarcoma	0.00536	0.0337	CbGeAlD
Orlistat—ABHD16A—myometrium—sarcoma	0.00503	0.0316	CbGeAlD
Orlistat—DAGLA—tendon—sarcoma	0.00487	0.0305	CbGeAlD
Orlistat—PLA2G7—seminal vesicle—sarcoma	0.00485	0.0304	CbGeAlD
Orlistat—ABHD12—myometrium—sarcoma	0.00472	0.0296	CbGeAlD
Orlistat—PLA2G7—hematopoietic system—sarcoma	0.00461	0.0289	CbGeAlD
Orlistat—ABHD16A—seminal vesicle—sarcoma	0.00455	0.0285	CbGeAlD
Orlistat—PLA2G7—connective tissue—sarcoma	0.00443	0.0278	CbGeAlD
Orlistat—ABHD12—seminal vesicle—sarcoma	0.00426	0.0267	CbGeAlD
Orlistat—PNLIP—hematopoietic system—sarcoma	0.00405	0.0254	CbGeAlD
Orlistat—DAGLA—testis—sarcoma	0.00403	0.0253	CbGeAlD
Orlistat—FASN—myometrium—sarcoma	0.00396	0.0248	CbGeAlD
Orlistat—PNLIP—connective tissue—sarcoma	0.0039	0.0245	CbGeAlD
Orlistat—DAGLB—tendon—sarcoma	0.00377	0.0237	CbGeAlD
Orlistat—FASN—seminal vesicle—sarcoma	0.00358	0.0224	CbGeAlD
Orlistat—PLA2G7—lymphoid tissue—sarcoma	0.00324	0.0203	CbGeAlD
Orlistat—DAGLB—testis—sarcoma	0.00312	0.0196	CbGeAlD
Orlistat—ABHD12—cardiac atrium—sarcoma	0.00307	0.0193	CbGeAlD
Orlistat—PLA2G7—tendon—sarcoma	0.00305	0.0191	CbGeAlD
Orlistat—DAGLB—liver—sarcoma	0.00295	0.0185	CbGeAlD
Orlistat—PLA2G7—bone marrow—sarcoma	0.00295	0.0185	CbGeAlD
Orlistat—ABHD16A—tendon—sarcoma	0.00286	0.0179	CbGeAlD
Orlistat—ABHD16A—bone marrow—sarcoma	0.00277	0.0174	CbGeAlD
Orlistat—ABHD12—tendon—sarcoma	0.00268	0.0168	CbGeAlD
Orlistat—FASN—uterus—sarcoma	0.00257	0.0161	CbGeAlD
Orlistat—PLA2G7—liver—sarcoma	0.00239	0.015	CbGeAlD
Orlistat—ABHD16A—testis—sarcoma	0.00237	0.0149	CbGeAlD
Orlistat—DAGLB—lymph node—sarcoma	0.00227	0.0142	CbGeAlD
Orlistat—ABHD12—testis—sarcoma	0.00222	0.0139	CbGeAlD
Orlistat—ABHD12—liver—sarcoma	0.0021	0.0132	CbGeAlD
Orlistat—PNLIP—liver—sarcoma	0.0021	0.0132	CbGeAlD
Orlistat—PLA2G4A—myometrium—sarcoma	0.0019	0.0119	CbGeAlD
Orlistat—FASN—testis—sarcoma	0.00186	0.0117	CbGeAlD
Orlistat—PLA2G7—lymph node—sarcoma	0.00183	0.0115	CbGeAlD
Orlistat—FASN—liver—sarcoma	0.00176	0.011	CbGeAlD
Orlistat—PLA2G4A—seminal vesicle—sarcoma	0.00172	0.0108	CbGeAlD
Orlistat—ABHD16A—lymph node—sarcoma	0.00172	0.0108	CbGeAlD
Orlistat—PLA2G4A—hematopoietic system—sarcoma	0.00163	0.0102	CbGeAlD
Orlistat—ABHD12—lymph node—sarcoma	0.00161	0.0101	CbGeAlD
Orlistat—PLA2G4A—connective tissue—sarcoma	0.00157	0.00987	CbGeAlD
Orlistat—PLA2G4A—smooth muscle tissue—sarcoma	0.00144	0.00903	CbGeAlD
Orlistat—FASN—lymph node—sarcoma	0.00135	0.00847	CbGeAlD
Orlistat—PLA2G4A—tendon—sarcoma	0.00108	0.00678	CbGeAlD
Orlistat—PLA2G4A—bone marrow—sarcoma	0.00105	0.00657	CbGeAlD
Orlistat—PLA2G4A—testis—sarcoma	0.000895	0.00562	CbGeAlD
Orlistat—PLA2G4A—lymph node—sarcoma	0.000649	0.00407	CbGeAlD
Orlistat—CYP3A4—hematopoietic system—sarcoma	0.000539	0.00338	CbGeAlD
Orlistat—Osteoarthritis—Epirubicin—sarcoma	0.000339	0.0019	CcSEcCtD
Orlistat—Feeling abnormal—Dactinomycin—sarcoma	0.000338	0.0019	CcSEcCtD
Orlistat—Gastrointestinal pain—Thiotepa—sarcoma	0.000338	0.0019	CcSEcCtD
Orlistat—Ill-defined disorder—Etoposide—sarcoma	0.000338	0.00189	CcSEcCtD
Orlistat—Gastrointestinal pain—Dactinomycin—sarcoma	0.000335	0.00188	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Vincristine—sarcoma	0.000334	0.00187	CcSEcCtD
Orlistat—Increased appetite—Doxorubicin—sarcoma	0.000334	0.00187	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—sarcoma	0.000332	0.00186	CcSEcCtD
Orlistat—Insomnia—Vincristine—sarcoma	0.000332	0.00186	CcSEcCtD
Orlistat—Paraesthesia—Vincristine—sarcoma	0.000329	0.00185	CcSEcCtD
Orlistat—Urticaria—Thiotepa—sarcoma	0.000328	0.00184	CcSEcCtD
Orlistat—Malaise—Etoposide—sarcoma	0.000328	0.00184	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—sarcoma	0.000328	0.00184	CcSEcCtD
Orlistat—Vertigo—Etoposide—sarcoma	0.000327	0.00183	CcSEcCtD
Orlistat—Body temperature increased—Thiotepa—sarcoma	0.000327	0.00183	CcSEcCtD
Orlistat—Abdominal pain—Thiotepa—sarcoma	0.000327	0.00183	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000325	0.00182	CcSEcCtD
Orlistat—Body temperature increased—Dactinomycin—sarcoma	0.000324	0.00182	CcSEcCtD
Orlistat—Abdominal pain—Dactinomycin—sarcoma	0.000324	0.00182	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—sarcoma	0.000321	0.0018	CcSEcCtD
Orlistat—Paraesthesia—Mitoxantrone—sarcoma	0.000321	0.0018	CcSEcCtD
Orlistat—Decreased appetite—Vincristine—sarcoma	0.000319	0.00179	CcSEcCtD
Orlistat—Cough—Etoposide—sarcoma	0.000317	0.00178	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vincristine—sarcoma	0.000316	0.00178	CcSEcCtD
Orlistat—Fatigue—Vincristine—sarcoma	0.000316	0.00177	CcSEcCtD
Orlistat—Convulsion—Etoposide—sarcoma	0.000315	0.00177	CcSEcCtD
Orlistat—Dyspepsia—Mitoxantrone—sarcoma	0.000314	0.00176	CcSEcCtD
Orlistat—Pain—Vincristine—sarcoma	0.000313	0.00176	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—sarcoma	0.000313	0.00176	CcSEcCtD
Orlistat—Dry skin—Epirubicin—sarcoma	0.00031	0.00174	CcSEcCtD
Orlistat—Decreased appetite—Mitoxantrone—sarcoma	0.00031	0.00174	CcSEcCtD
Orlistat—Chest pain—Etoposide—sarcoma	0.00031	0.00174	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	0.00031	0.00463	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—VEGFA—sarcoma	0.00031	0.00463	CbGpPWpGaD
Orlistat—Abdominal pain upper—Epirubicin—sarcoma	0.000309	0.00173	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—sarcoma	0.000308	0.00173	CcSEcCtD
Orlistat—Fatigue—Mitoxantrone—sarcoma	0.000308	0.00173	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000308	0.00173	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.000306	0.00458	CbGpPWpGaD
Orlistat—Discomfort—Etoposide—sarcoma	0.000306	0.00172	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—sarcoma	0.000306	0.00172	CcSEcCtD
Orlistat—Pain—Mitoxantrone—sarcoma	0.000305	0.00171	CcSEcCtD
Orlistat—Hypersensitivity—Thiotepa—sarcoma	0.000305	0.00171	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—MMP2—sarcoma	0.000303	0.00454	CbGpPWpGaD
Orlistat—Hypersensitivity—Dactinomycin—sarcoma	0.000302	0.0017	CcSEcCtD
Orlistat—Gastrointestinal pain—Vincristine—sarcoma	0.0003	0.00168	CcSEcCtD
Orlistat—Gastritis—Epirubicin—sarcoma	0.0003	0.00168	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—CXCR4—sarcoma	0.0003	0.00448	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CXCR4—sarcoma	0.0003	0.00448	CbGpPWpGaD
Orlistat—PNLIP—Disease—TLE1—sarcoma	0.000299	0.00446	CbGpPWpGaD
Orlistat—Anaphylactic shock—Etoposide—sarcoma	0.000297	0.00167	CcSEcCtD
Orlistat—Asthenia—Thiotepa—sarcoma	0.000297	0.00166	CcSEcCtD
Orlistat—Infection—Etoposide—sarcoma	0.000295	0.00165	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—sarcoma	0.000295	0.00165	CcSEcCtD
Orlistat—Asthenia—Dactinomycin—sarcoma	0.000294	0.00165	CcSEcCtD
Orlistat—Feeling abnormal—Mitoxantrone—sarcoma	0.000294	0.00165	CcSEcCtD
Orlistat—Asthma—Epirubicin—sarcoma	0.000293	0.00164	CcSEcCtD
Orlistat—Influenza—Epirubicin—sarcoma	0.000293	0.00164	CcSEcCtD
Orlistat—Pruritus—Thiotepa—sarcoma	0.000292	0.00164	CcSEcCtD
Orlistat—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000292	0.00164	CcSEcCtD
Orlistat—Abdominal pain—Vincristine—sarcoma	0.00029	0.00163	CcSEcCtD
Orlistat—Body temperature increased—Vincristine—sarcoma	0.00029	0.00163	CcSEcCtD
Orlistat—Skin disorder—Etoposide—sarcoma	0.000288	0.00162	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—sarcoma	0.000287	0.00161	CcSEcCtD
Orlistat—Hyperhidrosis—Etoposide—sarcoma	0.000287	0.00161	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—sarcoma	0.000287	0.00161	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—sarcoma	0.000286	0.00161	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—sarcoma	0.000285	0.0016	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	0.000285	0.00426	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	0.000285	0.00426	CbGpPWpGaD
Orlistat—Urticaria—Mitoxantrone—sarcoma	0.000284	0.00159	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—sarcoma	0.000283	0.00159	CcSEcCtD
Orlistat—Diarrhoea—Thiotepa—sarcoma	0.000283	0.00159	CcSEcCtD
Orlistat—Body temperature increased—Mitoxantrone—sarcoma	0.000282	0.00158	CcSEcCtD
Orlistat—Abdominal pain—Mitoxantrone—sarcoma	0.000282	0.00158	CcSEcCtD
Orlistat—Diarrhoea—Dactinomycin—sarcoma	0.000281	0.00157	CcSEcCtD
Orlistat—CYP3A4—liver—sarcoma	0.000279	0.00175	CbGeAlD
Orlistat—Gastritis—Doxorubicin—sarcoma	0.000277	0.00156	CcSEcCtD
Orlistat—PLA2G4A—Opioid Signalling—CREB1—sarcoma	0.000277	0.00414	CbGpPWpGaD
Orlistat—Dizziness—Thiotepa—sarcoma	0.000273	0.00153	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—sarcoma	0.000273	0.00153	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—CXCR4—sarcoma	0.000272	0.00407	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CXCR4—sarcoma	0.000272	0.00407	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Epirubicin—sarcoma	0.000272	0.00153	CcSEcCtD
Orlistat—Asthma—Doxorubicin—sarcoma	0.000271	0.00152	CcSEcCtD
Orlistat—Influenza—Doxorubicin—sarcoma	0.000271	0.00152	CcSEcCtD
Orlistat—Hypersensitivity—Vincristine—sarcoma	0.00027	0.00151	CcSEcCtD
Orlistat—PNLIP—Disease—NPM1—sarcoma	0.000269	0.00403	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PDGFRB—sarcoma	0.000269	0.00402	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	0.000269	0.00402	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	0.000269	0.00402	CbGpPWpGaD
Orlistat—Paraesthesia—Etoposide—sarcoma	0.000267	0.0015	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—sarcoma	0.000266	0.00149	CcSEcCtD
Orlistat—Hypersensitivity—Mitoxantrone—sarcoma	0.000263	0.00148	CcSEcCtD
Orlistat—Asthenia—Vincristine—sarcoma	0.000263	0.00148	CcSEcCtD
Orlistat—Vomiting—Thiotepa—sarcoma	0.000263	0.00147	CcSEcCtD
Orlistat—Infestation—Epirubicin—sarcoma	0.000261	0.00146	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—sarcoma	0.000261	0.00146	CcSEcCtD
Orlistat—Vomiting—Dactinomycin—sarcoma	0.000261	0.00146	CcSEcCtD
Orlistat—Rash—Thiotepa—sarcoma	0.000261	0.00146	CcSEcCtD
Orlistat—Dermatitis—Thiotepa—sarcoma	0.00026	0.00146	CcSEcCtD
Orlistat—Headache—Thiotepa—sarcoma	0.000259	0.00145	CcSEcCtD
Orlistat—Rash—Dactinomycin—sarcoma	0.000259	0.00145	CcSEcCtD
Orlistat—Decreased appetite—Etoposide—sarcoma	0.000258	0.00145	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000257	0.00384	CbGpPWpGaD
Orlistat—Renal failure—Epirubicin—sarcoma	0.000257	0.00144	CcSEcCtD
Orlistat—Gastrointestinal disorder—Etoposide—sarcoma	0.000256	0.00144	CcSEcCtD
Orlistat—Asthenia—Mitoxantrone—sarcoma	0.000256	0.00144	CcSEcCtD
Orlistat—Fatigue—Etoposide—sarcoma	0.000256	0.00144	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—sarcoma	0.000256	0.00143	CcSEcCtD
Orlistat—Pain—Etoposide—sarcoma	0.000254	0.00142	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—sarcoma	0.000254	0.00142	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—TLE1—sarcoma	0.000252	0.00377	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TLE1—sarcoma	0.000252	0.00377	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000252	0.00141	CcSEcCtD
Orlistat—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—sarcoma	0.000252	0.00376	CbGpPWpGaD
Orlistat—Diarrhoea—Vincristine—sarcoma	0.000251	0.00141	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	0.00025	0.00373	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Epirubicin—sarcoma	0.000247	0.00138	CcSEcCtD
Orlistat—Nausea—Thiotepa—sarcoma	0.000246	0.00138	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—MMP2—sarcoma	0.000245	0.00367	CbGpPWpGaD
Orlistat—Sinusitis—Epirubicin—sarcoma	0.000245	0.00137	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—sarcoma	0.000245	0.00137	CcSEcCtD
Orlistat—Diarrhoea—Mitoxantrone—sarcoma	0.000244	0.00137	CcSEcCtD
Orlistat—Nausea—Dactinomycin—sarcoma	0.000244	0.00137	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—JUN—sarcoma	0.000243	0.00364	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Etoposide—sarcoma	0.000243	0.00136	CcSEcCtD
Orlistat—Dizziness—Vincristine—sarcoma	0.000242	0.00136	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—sarcoma	0.000241	0.00135	CcSEcCtD
Orlistat—Infestation—Doxorubicin—sarcoma	0.000241	0.00135	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—sarcoma	0.000237	0.00133	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—sarcoma	0.000237	0.00133	CcSEcCtD
Orlistat—Urticaria—Etoposide—sarcoma	0.000236	0.00132	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—sarcoma	0.000235	0.00132	CcSEcCtD
Orlistat—Abdominal pain—Etoposide—sarcoma	0.000235	0.00132	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—sarcoma	0.000235	0.00132	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—sarcoma	0.000235	0.00132	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—JUN—sarcoma	0.000234	0.0035	CbGpPWpGaD
Orlistat—Haemorrhage—Epirubicin—sarcoma	0.000234	0.00131	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—sarcoma	0.000234	0.00131	CcSEcCtD
Orlistat—PNLIP—Disease—ENO2—sarcoma	0.000233	0.00349	CbGpPWpGaD
Orlistat—Vomiting—Vincristine—sarcoma	0.000233	0.00131	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—sarcoma	0.000233	0.0013	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—sarcoma	0.000231	0.0013	CcSEcCtD
Orlistat—Rash—Vincristine—sarcoma	0.000231	0.0013	CcSEcCtD
Orlistat—Dermatitis—Vincristine—sarcoma	0.000231	0.0013	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—sarcoma	0.000231	0.00129	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—sarcoma	0.00023	0.00129	CcSEcCtD
Orlistat—Headache—Vincristine—sarcoma	0.00023	0.00129	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	0.000229	0.00342	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	0.000229	0.00342	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Doxorubicin—sarcoma	0.000228	0.00128	CcSEcCtD
Orlistat—Vomiting—Mitoxantrone—sarcoma	0.000227	0.00127	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—sarcoma	0.000227	0.00127	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—HRAS—sarcoma	0.000225	0.00337	CbGpPWpGaD
Orlistat—Rash—Mitoxantrone—sarcoma	0.000225	0.00126	CcSEcCtD
Orlistat—Dermatitis—Mitoxantrone—sarcoma	0.000225	0.00126	CcSEcCtD
Orlistat—Headache—Mitoxantrone—sarcoma	0.000224	0.00125	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—sarcoma	0.000219	0.00123	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—SRC—sarcoma	0.000218	0.00326	CbGpPWpGaD
Orlistat—Haemoglobin—Doxorubicin—sarcoma	0.000218	0.00122	CcSEcCtD
Orlistat—Nausea—Vincristine—sarcoma	0.000218	0.00122	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—sarcoma	0.000217	0.00122	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—sarcoma	0.000217	0.00122	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—TEK—sarcoma	0.000215	0.00322	CbGpPWpGaD
Orlistat—Pharyngitis—Doxorubicin—sarcoma	0.000215	0.00121	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—sarcoma	0.000214	0.0012	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—sarcoma	0.000214	0.0012	CcSEcCtD
Orlistat—Asthenia—Etoposide—sarcoma	0.000213	0.00119	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—VEGFC—sarcoma	0.000213	0.00318	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFC—sarcoma	0.000213	0.00318	CbGpPWpGaD
Orlistat—Urethral disorder—Doxorubicin—sarcoma	0.000212	0.00119	CcSEcCtD
Orlistat—Nausea—Mitoxantrone—sarcoma	0.000212	0.00119	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—sarcoma	0.000212	0.00119	CcSEcCtD
Orlistat—FASN—Disease—TLE1—sarcoma	0.000211	0.00316	CbGpPWpGaD
Orlistat—Mediastinal disorder—Epirubicin—sarcoma	0.000211	0.00118	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—SRC—sarcoma	0.00021	0.00314	CbGpPWpGaD
Orlistat—Pruritus—Etoposide—sarcoma	0.00021	0.00118	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—TLE1—sarcoma	0.000209	0.00313	CbGpPWpGaD
Orlistat—Alopecia—Epirubicin—sarcoma	0.000207	0.00116	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—sarcoma	0.000205	0.00115	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—sarcoma	0.000204	0.00114	CcSEcCtD
Orlistat—Diarrhoea—Etoposide—sarcoma	0.000203	0.00114	CcSEcCtD
Orlistat—Flatulence—Epirubicin—sarcoma	0.000201	0.00113	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—sarcoma	0.0002	0.00112	CcSEcCtD
Orlistat—PNLIP—Disease—PLCG1—sarcoma	0.000198	0.00296	CbGpPWpGaD
Orlistat—Back pain—Epirubicin—sarcoma	0.000197	0.00111	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—ANGPT2—sarcoma	0.000197	0.00294	CbGpPWpGaD
Orlistat—Dizziness—Etoposide—sarcoma	0.000196	0.0011	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—sarcoma	0.000196	0.0011	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—sarcoma	0.000196	0.0011	CcSEcCtD
Orlistat—PNLIP—Metabolism—ENO2—sarcoma	0.000195	0.00292	CbGpPWpGaD
Orlistat—Mediastinal disorder—Doxorubicin—sarcoma	0.000195	0.0011	CcSEcCtD
Orlistat—PNLIP—Metabolism—HBA1—sarcoma	0.000194	0.0029	CbGpPWpGaD
Orlistat—Vision blurred—Epirubicin—sarcoma	0.000192	0.00108	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—sarcoma	0.000192	0.00107	CcSEcCtD
Orlistat—FASN—Disease—NPM1—sarcoma	0.000191	0.00285	CbGpPWpGaD
Orlistat—PNLIP—Disease—CXCR4—sarcoma	0.00019	0.00284	CbGpPWpGaD
Orlistat—Mental disorder—Doxorubicin—sarcoma	0.00019	0.00107	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—sarcoma	0.000189	0.00106	CcSEcCtD
Orlistat—Vomiting—Etoposide—sarcoma	0.000189	0.00106	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000189	0.00282	CbGpPWpGaD
Orlistat—Malnutrition—Doxorubicin—sarcoma	0.000189	0.00106	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—CTNNB1—sarcoma	0.000188	0.00281	CbGpPWpGaD
Orlistat—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000188	0.00281	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IL2—sarcoma	0.000188	0.00281	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IL2—sarcoma	0.000188	0.00281	CbGpPWpGaD
Orlistat—Rash—Etoposide—sarcoma	0.000187	0.00105	CcSEcCtD
Orlistat—Dermatitis—Etoposide—sarcoma	0.000187	0.00105	CcSEcCtD
Orlistat—Headache—Etoposide—sarcoma	0.000186	0.00104	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—sarcoma	0.000186	0.00104	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—sarcoma	0.000185	0.00104	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—EGFR—sarcoma	0.000184	0.00275	CbGpPWpGaD
Orlistat—Malaise—Epirubicin—sarcoma	0.000184	0.00103	CcSEcCtD
Orlistat—Vertigo—Epirubicin—sarcoma	0.000183	0.00103	CcSEcCtD
Orlistat—Back pain—Doxorubicin—sarcoma	0.000183	0.00102	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—sarcoma	0.000181	0.00102	CcSEcCtD
Orlistat—Palpitations—Epirubicin—sarcoma	0.00018	0.00101	CcSEcCtD
Orlistat—Cough—Epirubicin—sarcoma	0.000178	0.000998	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—sarcoma	0.000178	0.000998	CcSEcCtD
Orlistat—Convulsion—Epirubicin—sarcoma	0.000177	0.000991	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—VEGFC—sarcoma	0.000176	0.00264	CbGpPWpGaD
Orlistat—Nausea—Etoposide—sarcoma	0.000176	0.000989	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—sarcoma	0.000175	0.000982	CcSEcCtD
Orlistat—Myalgia—Epirubicin—sarcoma	0.000174	0.000974	CcSEcCtD
Orlistat—Chest pain—Epirubicin—sarcoma	0.000174	0.000974	CcSEcCtD
Orlistat—Anxiety—Epirubicin—sarcoma	0.000173	0.000971	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000172	0.000967	CcSEcCtD
Orlistat—Discomfort—Epirubicin—sarcoma	0.000172	0.000962	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—FLT1—sarcoma	0.00017	0.00254	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FLT1—sarcoma	0.00017	0.00254	CbGpPWpGaD
Orlistat—Malaise—Doxorubicin—sarcoma	0.00017	0.000955	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—sarcoma	0.00017	0.000952	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—sarcoma	0.00017	0.000951	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—PLCG1—sarcoma	0.000167	0.0025	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PLCG1—sarcoma	0.000167	0.0025	CbGpPWpGaD
Orlistat—Palpitations—Doxorubicin—sarcoma	0.000167	0.000935	CcSEcCtD
Orlistat—Oedema—Epirubicin—sarcoma	0.000166	0.000934	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—sarcoma	0.000166	0.000934	CcSEcCtD
Orlistat—PNLIP—Metabolism—PLCG1—sarcoma	0.000166	0.00248	CbGpPWpGaD
Orlistat—Infection—Epirubicin—sarcoma	0.000165	0.000928	CcSEcCtD
Orlistat—FASN—Disease—ENO2—sarcoma	0.000165	0.00247	CbGpPWpGaD
Orlistat—Cough—Doxorubicin—sarcoma	0.000165	0.000924	CcSEcCtD
Orlistat—DAGLB—Hemostasis—SRC—sarcoma	0.000164	0.00245	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SRC—sarcoma	0.000164	0.00245	CbGpPWpGaD
Orlistat—Convulsion—Doxorubicin—sarcoma	0.000163	0.000917	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—sarcoma	0.000163	0.000916	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—sarcoma	0.000162	0.000907	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—sarcoma	0.000161	0.000903	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CXCR4—sarcoma	0.000161	0.0024	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCR4—sarcoma	0.000161	0.0024	CbGpPWpGaD
Orlistat—Myalgia—Doxorubicin—sarcoma	0.000161	0.000901	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—sarcoma	0.000161	0.000901	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—sarcoma	0.00016	0.000898	CcSEcCtD
Orlistat—DAGLA—Hemostasis—VEGFA—sarcoma	0.00016	0.00239	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—VEGFA—sarcoma	0.00016	0.00239	CbGpPWpGaD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00016	0.000895	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—ATF1—sarcoma	0.000159	0.00238	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ATF1—sarcoma	0.000159	0.00238	CbGpPWpGaD
Orlistat—Discomfort—Doxorubicin—sarcoma	0.000159	0.00089	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—VEGFC—sarcoma	0.000158	0.00236	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—NRAS—sarcoma	0.000158	0.00236	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—NRAS—sarcoma	0.000158	0.00236	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	0.000158	0.00236	CbGpPWpGaD
Orlistat—Dry mouth—Doxorubicin—sarcoma	0.000157	0.000881	CcSEcCtD
Orlistat—Oedema—Doxorubicin—sarcoma	0.000154	0.000864	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—sarcoma	0.000154	0.000864	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—HRAS—sarcoma	0.000154	0.0023	CbGpPWpGaD
Orlistat—Infection—Doxorubicin—sarcoma	0.000153	0.000858	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000152	0.000851	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—sarcoma	0.000151	0.000847	CcSEcCtD
Orlistat—Insomnia—Epirubicin—sarcoma	0.000151	0.000844	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—sarcoma	0.00015	0.000839	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—sarcoma	0.000149	0.000838	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—sarcoma	0.000149	0.000835	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—sarcoma	0.000147	0.000822	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—CREB1—sarcoma	0.000146	0.00218	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CREB1—sarcoma	0.000146	0.00218	CbGpPWpGaD
Orlistat—Decreased appetite—Epirubicin—sarcoma	0.000145	0.000812	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—sarcoma	0.000144	0.000806	CcSEcCtD
Orlistat—Fatigue—Epirubicin—sarcoma	0.000144	0.000805	CcSEcCtD
Orlistat—Pain—Epirubicin—sarcoma	0.000142	0.000798	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—FLT1—sarcoma	0.000141	0.00211	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—JUN—sarcoma	0.000141	0.0021	CbGpPWpGaD
Orlistat—PNLIP—Disease—FOXO1—sarcoma	0.00014	0.0021	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00014	0.000787	CcSEcCtD
Orlistat—PNLIP—Disease—PDGFRB—sarcoma	0.00014	0.0021	CbGpPWpGaD
Orlistat—FASN—Disease—PLCG1—sarcoma	0.00014	0.00209	CbGpPWpGaD
Orlistat—Insomnia—Doxorubicin—sarcoma	0.000139	0.000781	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000139	0.00208	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PLCG1—sarcoma	0.000139	0.00207	CbGpPWpGaD
Orlistat—Paraesthesia—Doxorubicin—sarcoma	0.000138	0.000776	CcSEcCtD
Orlistat—FASN—Metabolism—ENO2—sarcoma	0.000138	0.00207	CbGpPWpGaD
Orlistat—PNLIP—Disease—PDGFRA—sarcoma	0.000138	0.00206	CbGpPWpGaD
Orlistat—FASN—Metabolism—HBA1—sarcoma	0.000137	0.00205	CbGpPWpGaD
Orlistat—Feeling abnormal—Epirubicin—sarcoma	0.000137	0.000769	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—sarcoma	0.000136	0.000763	CcSEcCtD
Orlistat—DAGLA—Hemostasis—KRAS—sarcoma	0.000136	0.00203	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—KRAS—sarcoma	0.000136	0.00203	CbGpPWpGaD
Orlistat—Dyspepsia—Doxorubicin—sarcoma	0.000136	0.00076	CcSEcCtD
Orlistat—FASN—Disease—CXCR4—sarcoma	0.000135	0.00201	CbGpPWpGaD
Orlistat—Decreased appetite—Doxorubicin—sarcoma	0.000134	0.000751	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CXCR4—sarcoma	0.000133	0.00199	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000133	0.000746	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—sarcoma	0.000133	0.000745	CcSEcCtD
Orlistat—Urticaria—Epirubicin—sarcoma	0.000132	0.000742	CcSEcCtD
Orlistat—Pain—Doxorubicin—sarcoma	0.000132	0.000739	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—ATF1—sarcoma	0.000132	0.00197	CbGpPWpGaD
Orlistat—Abdominal pain—Epirubicin—sarcoma	0.000132	0.000738	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—sarcoma	0.000132	0.000738	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—sarcoma	0.000127	0.000712	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—SRC—sarcoma	0.000126	0.00189	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Doxorubicin—sarcoma	0.000126	0.000706	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—IGF1R—sarcoma	0.000125	0.00186	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IGF1R—sarcoma	0.000125	0.00186	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PLCG1—sarcoma	0.000124	0.00186	CbGpPWpGaD
Orlistat—Hypersensitivity—Epirubicin—sarcoma	0.000123	0.000688	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—sarcoma	0.000122	0.000686	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—sarcoma	0.000122	0.000683	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—sarcoma	0.000122	0.000683	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—NRAS—sarcoma	0.000121	0.00181	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—sarcoma	0.000121	0.0018	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—sarcoma	0.000121	0.0018	CbGpPWpGaD
Orlistat—Asthenia—Epirubicin—sarcoma	0.000119	0.00067	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—FOXO1—sarcoma	0.000119	0.00177	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FOXO1—sarcoma	0.000119	0.00177	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—IL2—sarcoma	0.000119	0.00177	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL2—sarcoma	0.000119	0.00177	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PDGFRB—sarcoma	0.000118	0.00177	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PDGFRB—sarcoma	0.000118	0.00177	CbGpPWpGaD
Orlistat—Pruritus—Epirubicin—sarcoma	0.000118	0.000661	CcSEcCtD
Orlistat—FASN—Metabolism—PLCG1—sarcoma	0.000117	0.00175	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PDGFRA—sarcoma	0.000117	0.00174	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PDGFRA—sarcoma	0.000117	0.00174	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—sarcoma	0.000115	0.00172	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—sarcoma	0.000115	0.00172	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000115	0.00172	CbGpPWpGaD
Orlistat—Diarrhoea—Epirubicin—sarcoma	0.000114	0.000639	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—sarcoma	0.000113	0.000636	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—sarcoma	0.000113	0.00169	CbGpPWpGaD
Orlistat—Asthenia—Doxorubicin—sarcoma	0.00011	0.00062	CcSEcCtD
Orlistat—Dizziness—Epirubicin—sarcoma	0.00011	0.000617	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—sarcoma	0.000109	0.000611	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—IL2—sarcoma	0.000108	0.00161	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL2—sarcoma	0.000108	0.00161	CbGpPWpGaD
Orlistat—PNLIP—Disease—KIT—sarcoma	0.000107	0.0016	CbGpPWpGaD
Orlistat—Vomiting—Epirubicin—sarcoma	0.000106	0.000594	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—sarcoma	0.000105	0.000591	CcSEcCtD
Orlistat—Rash—Epirubicin—sarcoma	0.000105	0.000589	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—sarcoma	0.000105	0.000588	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—KRAS—sarcoma	0.000104	0.00156	CbGpPWpGaD
Orlistat—Headache—Epirubicin—sarcoma	0.000104	0.000585	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—IGF1R—sarcoma	0.000103	0.00154	CbGpPWpGaD
Orlistat—PNLIP—Disease—CREB1—sarcoma	0.000102	0.00152	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—sarcoma	0.000102	0.000571	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.0001	0.0015	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.0001	0.0015	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	9.94e-05	0.00149	CbGpPWpGaD
Orlistat—FASN—Disease—FOXO1—sarcoma	9.94e-05	0.00149	CbGpPWpGaD
Orlistat—FASN—Disease—PDGFRB—sarcoma	9.92e-05	0.00148	CbGpPWpGaD
Orlistat—Nausea—Epirubicin—sarcoma	9.89e-05	0.000555	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—FOXO1—sarcoma	9.84e-05	0.00147	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PDGFRB—sarcoma	9.82e-05	0.00147	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KDR—sarcoma	9.82e-05	0.00147	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KDR—sarcoma	9.82e-05	0.00147	CbGpPWpGaD
Orlistat—Vomiting—Doxorubicin—sarcoma	9.79e-05	0.000549	CcSEcCtD
Orlistat—FASN—Disease—PDGFRA—sarcoma	9.77e-05	0.00146	CbGpPWpGaD
Orlistat—Rash—Doxorubicin—sarcoma	9.71e-05	0.000545	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—sarcoma	9.7e-05	0.000544	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PDGFRA—sarcoma	9.67e-05	0.00144	CbGpPWpGaD
Orlistat—Headache—Doxorubicin—sarcoma	9.65e-05	0.000541	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2—sarcoma	9.16e-05	0.00137	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—sarcoma	9.15e-05	0.000513	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—KIT—sarcoma	9.04e-05	0.00135	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KIT—sarcoma	9.04e-05	0.00135	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NRAS—sarcoma	9.04e-05	0.00135	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—NRAS—sarcoma	9.04e-05	0.00135	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	8.99e-05	0.00134	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—sarcoma	8.88e-05	0.00133	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	8.75e-05	0.00131	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CREB1—sarcoma	8.61e-05	0.00129	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CREB1—sarcoma	8.61e-05	0.00129	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	8.43e-05	0.00126	CbGpPWpGaD
Orlistat—PNLIP—Disease—MDM2—sarcoma	8.43e-05	0.00126	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—sarcoma	8.24e-05	0.00123	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—sarcoma	8.24e-05	0.00123	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KDR—sarcoma	8.14e-05	0.00122	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	8.05e-05	0.0012	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SRC—sarcoma	8e-05	0.0012	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.88e-05	0.00118	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—sarcoma	7.79e-05	0.00116	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—sarcoma	7.78e-05	0.00116	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—sarcoma	7.78e-05	0.00116	CbGpPWpGaD
Orlistat—FASN—Disease—KIT—sarcoma	7.57e-05	0.00113	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KIT—sarcoma	7.49e-05	0.00112	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	7.44e-05	0.00111	CbGpPWpGaD
Orlistat—PNLIP—Disease—CTNNB1—sarcoma	7.27e-05	0.00109	CbGpPWpGaD
Orlistat—FASN—Disease—CREB1—sarcoma	7.21e-05	0.00108	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CREB1—sarcoma	7.13e-05	0.00107	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MDM2—sarcoma	7.12e-05	0.00106	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MDM2—sarcoma	7.12e-05	0.00106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCR4—sarcoma	6.84e-05	0.00102	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—sarcoma	6.62e-05	0.000989	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—sarcoma	6.62e-05	0.000989	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	6.61e-05	0.000989	CbGpPWpGaD
Orlistat—PNLIP—Disease—SRC—sarcoma	6.57e-05	0.000982	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—sarcoma	6.36e-05	0.000952	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—sarcoma	6.36e-05	0.000952	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TLE1—sarcoma	6.35e-05	0.000949	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRAS—sarcoma	6.32e-05	0.000945	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—sarcoma	6.2e-05	0.000928	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—sarcoma	6.2e-05	0.000928	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JUN—sarcoma	6.19e-05	0.000926	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JUN—sarcoma	6.19e-05	0.000926	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—sarcoma	6.14e-05	0.000919	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—sarcoma	6.14e-05	0.000919	CbGpPWpGaD
Orlistat—FASN—Disease—MDM2—sarcoma	5.96e-05	0.000892	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO2—sarcoma	5.93e-05	0.000887	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MDM2—sarcoma	5.9e-05	0.000882	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HBA1—sarcoma	5.89e-05	0.000881	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—sarcoma	5.89e-05	0.00088	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—sarcoma	5.76e-05	0.000861	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SRC—sarcoma	5.55e-05	0.00083	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SRC—sarcoma	5.55e-05	0.00083	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—sarcoma	5.44e-05	0.000813	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—sarcoma	5.41e-05	0.000809	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—sarcoma	5.41e-05	0.000809	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFC—sarcoma	5.36e-05	0.000801	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—sarcoma	5.34e-05	0.000799	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—sarcoma	5.34e-05	0.000799	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—sarcoma	5.27e-05	0.000788	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—sarcoma	5.14e-05	0.000769	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—sarcoma	5.14e-05	0.000769	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—sarcoma	5.13e-05	0.000767	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—sarcoma	5.09e-05	0.000761	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PLCG1—sarcoma	5.03e-05	0.000752	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—sarcoma	4.98e-05	0.000744	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—sarcoma	4.98e-05	0.000744	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—sarcoma	4.87e-05	0.000728	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—sarcoma	4.87e-05	0.000728	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—sarcoma	4.72e-05	0.000706	CbGpPWpGaD
Orlistat—FASN—Disease—SRC—sarcoma	4.65e-05	0.000695	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—sarcoma	4.63e-05	0.000691	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SRC—sarcoma	4.6e-05	0.000688	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—sarcoma	4.6e-05	0.000687	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—sarcoma	4.6e-05	0.000687	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—sarcoma	4.48e-05	0.00067	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—sarcoma	4.47e-05	0.000669	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—sarcoma	4.43e-05	0.000662	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FLT1—sarcoma	4.28e-05	0.00064	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLCG1—sarcoma	4.21e-05	0.000629	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—sarcoma	4.17e-05	0.000623	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—sarcoma	4.12e-05	0.000617	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—sarcoma	4.12e-05	0.000616	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—sarcoma	4.09e-05	0.000611	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—sarcoma	4.09e-05	0.000611	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—sarcoma	4.08e-05	0.000609	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCR4—sarcoma	4.04e-05	0.000605	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—sarcoma	4.03e-05	0.000603	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—sarcoma	4.01e-05	0.0006	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ATF1—sarcoma	4e-05	0.000598	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—sarcoma	3.96e-05	0.000593	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—sarcoma	3.91e-05	0.000584	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—sarcoma	3.91e-05	0.000584	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—sarcoma	3.85e-05	0.000576	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—sarcoma	3.81e-05	0.00057	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CREB1—sarcoma	3.67e-05	0.000548	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—sarcoma	3.41e-05	0.00051	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—sarcoma	3.39e-05	0.000506	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—sarcoma	3.27e-05	0.000489	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—sarcoma	3.24e-05	0.000484	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—sarcoma	3.14e-05	0.000469	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—sarcoma	3.03e-05	0.000453	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FOXO1—sarcoma	2.99e-05	0.000446	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFRB—sarcoma	2.98e-05	0.000446	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFRA—sarcoma	2.93e-05	0.000439	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—sarcoma	2.9e-05	0.000434	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—sarcoma	2.71e-05	0.000405	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—sarcoma	2.47e-05	0.000369	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIT—sarcoma	2.28e-05	0.00034	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—sarcoma	2.28e-05	0.00034	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CREB1—sarcoma	2.17e-05	0.000324	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—sarcoma	2.07e-05	0.00031	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—sarcoma	1.96e-05	0.000293	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—sarcoma	1.79e-05	0.000268	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—sarcoma	1.66e-05	0.000249	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—sarcoma	1.6e-05	0.000239	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—sarcoma	1.56e-05	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—sarcoma	1.56e-05	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—sarcoma	1.55e-05	0.000231	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—sarcoma	1.4e-05	0.000209	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—sarcoma	1.39e-05	0.000208	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HBA1—sarcoma	1.38e-05	0.000206	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—sarcoma	1.36e-05	0.000203	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—sarcoma	1.34e-05	0.000201	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—sarcoma	1.25e-05	0.000187	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—sarcoma	1.22e-05	0.000183	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLCG1—sarcoma	1.18e-05	0.000176	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—sarcoma	1.16e-05	0.000173	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—sarcoma	1.03e-05	0.000154	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—sarcoma	9.83e-06	0.000147	CbGpPWpGaD
